MINNEAPOLIS & LUGANO, Switzerland--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced the successful completion of two phase 3 trials of Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV). Both clinical trials successfully met the primary efficacy endpoint of complete response for the 0-24 hour time period following surgery for the selected dose of 0.075 mg. In addition, both trials achieved the secondary endpoints of complete response for the 0-48 and 0-72 hour time periods. The incidence, pattern, and intensity of adverse events were similar among treatment groups, and the most frequently observed side effects were headache and constipation.
